Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline clinical and demographic characteristics of the study cohort, as well as compliance and radiographic response (RECIST) to chemotherapy

From: Safety and feasibility of fasting in combination with platinum-based chemotherapy

Characteristic Median (range) Number (%)
Age 61 (31–75)  
Gender Female 17 (85 %)
Male 3 (15 %)
Race Caucasian 8 (40 %)
Hispanic 9 (45 %)
Black 2 (10 %)
Asian 1 (5 %)
ECOG Performance Status 0 12 (60 %)
1 8 (40 %)
Total Fasting Cycles Completed 1 3 (15 %)
2 15 (75 %)
>2 2 (10 %)
Best objective (RECIST) response CR 2 (10 %)
PR 6 (30 %)
SD 3 (15 %)
PD 1 (5 %)
N/A0 (adjuvant therapy) 8 (40 %)
  1. CR Complete response, PR Partial response, SD, Stable disease, PD Progressive disease